NEW YORK, July 3 – Inpharmatica has received 31.25 million pounds ($43.9 million) in second round institutional funding, the company announced Tuesday. 

Inpharmatica, based in London, received funds from the European company Dresdner Kleinwort Capital, Abingworth Management of London, Glide Investment in The Netherlands, and Vertex Management in Singapore. Inpharmatica is now worth approximately 56 million pounds, according to the company.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.